PH12019500479A1 - Compositions for treating dementia - Google Patents

Compositions for treating dementia

Info

Publication number
PH12019500479A1
PH12019500479A1 PH12019500479A PH12019500479A PH12019500479A1 PH 12019500479 A1 PH12019500479 A1 PH 12019500479A1 PH 12019500479 A PH12019500479 A PH 12019500479A PH 12019500479 A PH12019500479 A PH 12019500479A PH 12019500479 A1 PH12019500479 A1 PH 12019500479A1
Authority
PH
Philippines
Prior art keywords
compositions
treating dementia
dementia
treating
kits
Prior art date
Application number
PH12019500479A
Other languages
English (en)
Inventor
Steven Hoffman
Original Assignee
Steven Hoffman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Steven Hoffman filed Critical Steven Hoffman
Publication of PH12019500479A1 publication Critical patent/PH12019500479A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PH12019500479A 2016-09-12 2019-03-05 Compositions for treating dementia PH12019500479A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662393140P 2016-09-12 2016-09-12
US201762507531P 2017-05-17 2017-05-17
PCT/US2017/050653 WO2018049141A1 (en) 2016-09-12 2017-09-08 Compositions for treating dementia

Publications (1)

Publication Number Publication Date
PH12019500479A1 true PH12019500479A1 (en) 2019-07-29

Family

ID=59901615

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12019500479A PH12019500479A1 (en) 2016-09-12 2019-03-05 Compositions for treating dementia

Country Status (12)

Country Link
US (1) US10300077B2 (enExample)
EP (1) EP3509639A1 (enExample)
JP (1) JP2019526612A (enExample)
KR (1) KR20190072521A (enExample)
CN (2) CN110177572A (enExample)
AU (1) AU2017322332A1 (enExample)
BR (1) BR112019004540A2 (enExample)
CA (1) CA3036511A1 (enExample)
IL (1) IL265255A (enExample)
MX (1) MX2019002673A (enExample)
PH (1) PH12019500479A1 (enExample)
WO (1) WO2018049141A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL237739B1 (pl) 2018-06-06 2021-05-17 Univ Gdanski Genisteina do zastosowania do leczenia choroby Alzheimera
AU2020276605A1 (en) 2019-05-14 2022-01-20 Tyme, Inc. Compositions and methods for treating cancer
US10905698B1 (en) * 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03161442A (ja) 1989-11-21 1991-07-11 Chiyouseidou Seiyaku Kk コール酸又はそのナトリウム塩からなる脳代謝改善剤
JPH06100466A (ja) * 1992-02-14 1994-04-12 Tsumura & Co ストレス性脳神経細胞器質障害防御剤
US5733926A (en) * 1996-12-13 1998-03-31 Gorbach; Sherwood L. Isoflavonoids for treatment and prevention of alzheimer dementia and reduced cognitive functions
US5952374A (en) * 1997-09-29 1999-09-14 Protein Technologies International, Inc. Method for inhibiting the development of Alzheimer's disease and related dementias- and for preserving cognitive function
US20040044080A1 (en) * 1997-10-28 2004-03-04 Place Virgil A. Treatment of dyspareunia with topically administered nitroglycerin formulations
JP4609875B2 (ja) * 2001-07-31 2011-01-12 有限会社大長企画 健康食品
US7338971B2 (en) 2001-08-30 2008-03-04 El-Naggar Mawaheb M Treatment of inflammatory, cancer, and thrombosis disorders
JP5384777B2 (ja) * 2001-12-18 2014-01-08 有限会社大長企画 強筋肉剤、抗炎症剤
DE602005025391D1 (de) * 2004-11-01 2011-01-27 Seo Hong Yoo Verfahren und zusammensetzungen zur verringerung der neurodegeneration bei amyotrophischer lateralsklerose
CA2602386A1 (en) 2005-03-25 2006-10-05 Merck & Co., Inc. Method of treating men with testosterone supplement and 5alpha-reductase inhibitor
WO2007016766A1 (en) * 2005-08-05 2007-02-15 Nuvo Research Inc. Transdermal drug delivery formulation
EP3045177A1 (en) * 2005-09-26 2016-07-20 The Regents of The University of California Estriol therapy for autoimmune and neurodegenerative diseases and disorders
EP2046325A1 (en) * 2006-08-02 2009-04-15 Brinton, Roberta, Diaz Phytoestrogenic formulations and uses thereof
WO2010118282A1 (en) * 2009-04-09 2010-10-14 Amicus Therapeutics, Inc. Methods for preventing and/or treating degenerative disorders of the central nervous system
CN102397550B (zh) 2011-08-30 2013-05-08 广东医学院 一组由阿司匹林与雌激素组成的防治骨质疏松症的药物组合物
EP2781214A1 (en) 2013-03-22 2014-09-24 Chemo Research, S.L. Formulation of amorphous calcium L-5-methyltetrahydrofolate (L-5-MTHF-Ca)
US9872865B2 (en) 2013-03-24 2018-01-23 Amylyx Pharmaceuticals Inc. Compositions for improving cell viability and methods of use thereof
JP2016520615A (ja) * 2013-05-31 2016-07-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． アルツハイマー病を処置するためのｉｌ−１アンタゴニストを使用する方法

Also Published As

Publication number Publication date
JP2019526612A (ja) 2019-09-19
US10300077B2 (en) 2019-05-28
CA3036511A1 (en) 2018-03-15
CN110177572A (zh) 2019-08-27
US20180071316A1 (en) 2018-03-15
WO2018049141A1 (en) 2018-03-15
IL265255A (en) 2019-05-30
MX2019002673A (es) 2019-07-04
AU2017322332A1 (en) 2019-04-04
BR112019004540A2 (pt) 2019-05-28
KR20190072521A (ko) 2019-06-25
EP3509639A1 (en) 2019-07-17
CN114796236A (zh) 2022-07-29
WO2018049141A4 (en) 2018-05-03

Similar Documents

Publication Publication Date Title
AU2016263598A8 (en) Methods and kits for treating depression
PH12019502171A1 (en) Composition and methods for immunooncology
PH12018501159A1 (en) Composition and methods for immunooncology
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
PH12018501378A1 (en) Compositions and methods for the treatment of hemoglobinopathies
AU2019268074A1 (en) Methods for treating hepcidin-mediated disorders
MX2018012016A (es) Compuestos biciclicos.
MX2020005213A (es) Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos.
EA201891910A1 (ru) Гетероарильные ингибиторы pad4
MX2018006632A (es) Inhibidores biciclicos de peptidilarginina deiminasa 4 (pad4).
EP4351045A3 (en) Methods and apparatus for setting subband csi-related parameters
PH12018502137A1 (en) Anti-complement factor bb antibodies and uses thereof
PH12018502020A1 (en) Methods for treating and preventing c. difficile infection
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
MX2018006700A (es) Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4).
EP3204038A4 (en) Compositions and kits for treating pruritus and methods of using the same
ZA201905895B (en) Kits and methods for preparing pathogen-inactivated platelet compositions
PH12017501864A1 (en) Compositions and methods for treating autism
GB2569488A (en) PD-1 specific aptamers
PH12019500479A1 (en) Compositions for treating dementia
GEP201706795B (en) Hexahydrofuropyrroles as pde1 inhibitors
MX2019004182A (es) Proceso para la fabricacion de 2,6-dimetil-5-hepten-1-al.
BR112017024855A2 (pt) métodos de produção de aldc
MX383313B (es) Compuestos de quinolinilciclohexilpropanamida sustituidos y metodos mejorados para su preparacion
MX383947B (es) Composiciones de colágeno 7 y métodos para usar las mismas.